MHRA strengthens safety warnings on Botulinum Toxin

The Medicines and Healthcare products Regulatory Agency (MHRA) has strengthened safety warnings for all botulinum toxin type A products following reports of rare cases of botulism linked to their use.

Widely used in both medical treatments and aesthetic procedures, botulinum toxin products are considered effective when administered correctly. However, the MHRA is reinforcing guidance after identifying very rare cases where the toxin's effects spread beyond the injection site, potentially leading to botulism, a serious and potentially life-threatening condition.

Updated product information, including patient leaflets, now provides clearer warnings about the risk of iatrogenic botulism. Patients are advised to seek immediate medical attention if they experience symptoms such as difficulty swallowing, slurred speech, breathing difficulties or muscle weakness. These may occur within days or up to four weeks after treatment.

Dr Alison Cave, MHRA Chief Safety Officer, said:

“Botulinum toxin products are effective for a number of different medical and cosmetic purposes when used correctly. However, these strengthened warnings are an important reminder that, in rare cases, serious side effects can occur.”

The risk of adverse reactions may be higher in patients with certain underlying conditions, when high doses are used or when products are administered outside licensed indications or sites.

The MHRA is also warning against unlicensed or counterfeit products, which do not meet UK safety standards. Investigations have been launched following a spike in hospital admissions linked to such products last year.

Practitioners are urged to ensure treatments are delivered within licensed guidelines, while patients are encouraged to choose appropriately qualified professionals and report side effects via the Yellow Card scheme.